Article thumbnail

Hepatocellular Carcinoma: Focus on Different Aspects of Management

By Sene Waly Raphael, Zhang Yangde and Chen YuXiang

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third cause of cancer-related mortality worldwide. Its incidence is clearly arising comprised by the prevalence of major risk factors mainly hepatitis B and hepatitis C. The population at risk is composed of chronic liver patients at the stage of extensive fibrosis or cirrhosis. The monitoring programs of this population have allowed early detection of disease management to promote a radical therapy. Understanding the carcinogenic process and the mastery of the staging systems remain essential keys in diagnosis and treatment of HCC. Recent advances in diagnosis and new treatments have made important impacts on the disease by increasing survival rates and improving quality of life for HCC patients. This paper outlines the different management aspects of HCC which include epidemiology, prevention, carcinogenesis, staging systems, diagnosis, surveillance, and the treatment

Topics: Review Article
Publisher: International Scholarly Research Network
OAI identifier: oai:pubmedcentral.nih.gov:3359687
Provided by: PubMed Central

Suggested articles

Citations

  1. (2010). A .F o r n e r ,M .E .R e i g ,C .R .d eL o p e ,a n dJ .B r u i x ,“ C u r r e n t strategy for staging and treatment: the BCLC update and future prospects,”
  2. (2004). a l aa n dJ .B r u i x ,Management of Hepatocellular Carcinoma. Management of Patients with Viral Hepatitis,
  3. (1999). A new prognostic classification for predicting survival in patients with hepatocellular carcinoma,”
  4. (2004). Alcohol and hepatocellular carcinoma,”
  5. and hepatocellular carcinoma,”
  6. (2008). c h o t t ,A .B e r g k ,a n dT .B e r g ,“ S t r a t e g i e sf o rt h ep r e v e n -tion of hepatocellular carcinoma in the context of chronic viral hepatitis,” Zeitschrift fur Gastroenterologie,
  7. Carcinome h´ epatocellulaire: ´ epid´ emiologie, physiopathologie et diagnostic,” H´ epatologie .
  8. Chemoembolization (trans-arterial chemoembolization or TACE), http://www.medicinenet.com/liver cancer/page10.htm.
  9. Chronic Hepatitis Virus Infection in Chinese Children,
  10. (2001). Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for t h eS t u d yo ft h eL i v e r ,
  11. (2011). Clinical practice. Chronic hepatitis C infection,” The New England
  12. (2008). Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score,”
  13. (2002). Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients,”
  14. (2008). Curbing the liver cancer epidemic in
  15. (2011). Depicting the role of TP53 in hepatocellular carcinoma progression,”
  16. (2004). Diagnosis and staging of hepatocellular carcinoma,”
  17. (2009). Diagnosis of hepatocellular carcinoma,”
  18. (2004). Diagnosis, staging and treatment of hepatocellular carcinoma,”
  19. (2009). Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients?”
  20. (2008). E l - S e r a g ,J .A .M a r r e r o ,L .R u d o l p h ,a n dK .R .R e d d y , “Diagnosis and treatment of hepatocellular carcinoma,”
  21. (2010). Epidemiology and management of hepatocellular carcinoma,”
  22. (2005). Epidemiology and natural history of hepatocellular carcinoma,”
  23. (2011). Epidemiology and pathogenesis of hepatocellular carcinoma,” in Hepatocellular Carcinoma,K .M .M c M a s t e r sa n dJ .N .V a u t h e y ,E d s . ,c h a p t e
  24. (2010). Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma,”
  25. (2009). Epidemiology of hepatocellular carcinoma in
  26. (2010). Epidemiology of hepatocellular carcinoma,”
  27. (2009). F .S h a r i ff,I .J .C o x ,A .I .G o m a a ,S .A .K h a n
  28. (2004). Focus on hepatocellular carcinoma,”
  29. (2010). Future perspectives in hepatocellular carcinoma,”
  30. (2010). Global burden of Aflatoxin-induced hepatocellular carcinoma: a risk assessment,”
  31. (2003). Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC)
  32. (2008). Guidelines for the use of contrast-enhanced ultrasound in hepatocellular carcinoma,”
  33. (2010). H.Nordenstedt,D.L.White,andH.B.El-Serag,“Thechanging pattern of epidemiology in hepatocellular carcinoma,” Digestive and Liver Disease,
  34. (2010). Hautefeuille et al., “Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines:
  35. (2011). HBV-related HCC, clinical issues and therapy,”
  36. (2003). Hepatitis B virus and hepatocellular carcinoma,” J o u r n a lo fH e p a t o l o g y ,
  37. (2007). Hepatitis B virus-related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors,”
  38. (2001). Hepatocellular carcinoma and aflatoxin exposure in Zhuqing Village, Fusui County,
  39. (2007). Hepatocellular carcinoma development in cirrhosis,”BestPracticeandResearch,vol.21,no.1,pp.161–173,
  40. (1997). Hepatocellular carcinoma p53 G > T transversions at codon 249: the fingerprint of aflatoxin exposure?”
  41. (2004). Hepatocellular carcinoma with nonalcoholic steatohepatitis,”
  42. (2009). Hepatocellular carcinoma-epidemiological trends and risk factors,”
  43. (2008). Hepatocellular carcinoma,”
  44. (2000). Hepatocellular carcinoma,” J o u r n a lo fH e p a t o l -ogy,
  45. (2010). Hepatocellular carcinoma: current management,”
  46. (2008). Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis,”
  47. Hepatocellular carcinoma: global epidemiology,” Digestive and Liver Disease,
  48. Hepatocellular carcinoma: screening and staging,”ClinicsinLiverDisease,vol.15,no.2,pp.323–334,2011.
  49. (1999). How to improve the present TNM staging system,”
  50. (2009). In vitro recapitulating of TP53 mutagenesis in hepatocellular carcinoma associated with dietary aflatoxin
  51. (2010). Inherited hepatocellular carcinoma,”
  52. (2010). Intra-arterial therapies for hepatocellular carcinoma: where do we stand?”
  53. (2009). Liver resection for HCC with cirrhosis: surgical perspectives out of EASL/AASLD guidelines,” European Journ a lo fS u r g i c a lO n c o l o g y ,
  54. (2009). Liver resection vs radio-frequencyablationinthetreatmentofsmallhepatocellular carcinoma,”
  55. (2005). Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations,” Liver Transplantation,
  56. (2003). Liver transplantation for hepatocellular carcinoma in cirrhotic patients,”
  57. (2002). Liver transplantation for hepatocellular carcinoma,”
  58. (2002). Liver transplantation for hepatocellular carcinoma: an Asian perspective,”
  59. (1996). Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis,”
  60. (1999). Locoregional treatments for hepatocellularcarcinoma,”BestPracticeandResearchClinicalGastroenterology,
  61. (2009). Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit
  62. (2009). Management of hepatocellular carcinoma in the age of liver transplantation,”
  63. (2005). Management of hepatocellular carcinoma,”
  64. (2011). Management of hepatocellular carcinoma: an update,”
  65. Meld information for liver transplant professionals,
  66. (2005). Metastasis and recurrence after surgical resection of hepatocellular carcinoma: recent progress in clinical and related basic aspects,”
  67. (2010). Molecular approaches to treatment of hepatocellular carcinoma,”
  68. (2010). Molecular classification of hepatocellular carcinoma,”
  69. (2011). Natural history of chronic hepatitis
  70. (2007). Non-alcoholic steatohepatitis and cancer,”
  71. (2007). Non-alcoholic steatohepatitis and hepatocellular carcinoma: lessons from hepatocyte-specific phosphatase and tensin homolog (PTEN)-deficient mice,”
  72. (2010). Nonalcoholic steatohepatitisassociated hepatocellular carcinoma: our case series and literature review,”
  73. (2008). Novel advancements in the management of hepatocellular carcinoma in
  74. (2010). o n c a l l i ,Y .N .P a r k ,a n dL .d iT o m m a s o ,“ H i s t o p a t h o l o g -ical classification of hepatocellular carcinoma,” Digestive and Liver Disease,
  75. (2008). Omata,“Hepatocellularcarcinomainviralhepatitis:improving standard therapy,”
  76. (2010). Percutaneous ablation of hepatocellular carcinoma: current status,”
  77. (2004). Percutaneous ablation of hepatocellular carcinoma: state-of-the-art,”
  78. (2007). Percutaneous laser ablation of small hepatocellular carcinoma,”
  79. (2003). PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling.,”
  80. (2009). Prevention of hepatocellular carcinoma in hepatitis B virus infection,”
  81. (2011). Prevention of hepatocellular carcinoma,”
  82. (2005). Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an
  83. (2003). Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan integrated staging score (JIS score),”
  84. (2011). Progression of liver cirrhosis to HCC: an application of hidden
  85. (2008). R.Mazzanti,L.Gramantieri,andL.Bolondi,“Hepatocellular carcinoma: epidemiology and clinical aspects,”
  86. (2010). Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases,”
  87. (2008). Radiological diagnosis of hepatocellular carcinoma,”
  88. (1957). Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation,”
  89. (2007). Roberts,“Livertransplantationforhepatocellularcarcinoma: validationoftheUCSF-expandedcriteriabasedonpreoperative imaging,”
  90. (2006). Roles of p53 in carcinogenesis, diagnosis and treatment of hepatocellular carcinoma,”
  91. (2001). S m e l a ,S .S .C u r r i e r ,E .A .B a i l e y ,a n dJ .M .E s s i g m a n n , “The chemistry and biology of aflatoxin B1: from mutational spectrometry to carcinogenesis,” Carcinogenesis,
  92. (2003). Staging of hepatocellular carcinoma,”
  93. (2004). Staging systems in hepatocellular carcinoma,”
  94. (2005). Staging systems in hepatocellularcarcinoma,”Hepato-Pancreato-BiliaryJournal,
  95. (2008). Surgical resection of hepatocellular carcinoma,”
  96. (2009). Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis,”
  97. (2011). Survival after Yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across barcelona clinic liver cancer stages: a European evaluation,”
  98. (2008). Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems,”
  99. (2008). Systemic therapy for hepatocellularcarcinoma:cytotoxicchemotherapy,targetedtherapy and immunotherapy,”
  100. (2006). Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?”
  101. (2009). Systemic treatment in hepatocellular carcinoma; ‘ as m a l ls t e pf o rm a n .
  102. (2000). Tagger et al., “Etiology of hepatocellular carcinoma in Italian patients with and without cirrhosis,”
  103. (1995). Th´ e p o t ,P .B e r t h e l o t ,a n dC .B r e c h o t ,
  104. (2004). The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available?”
  105. The Japanese integrated staging score using liver damage grade for hepatocellular carcinoma in patients after hepatectomy,”
  106. (2004). The role and limitation of living donor liver transplantation for hepatocellular carcinoma,” Liver Transplantation,
  107. (2007). The role of the IGF system in cancer growth and metastasis: overview andrecentinsights,”EndocrineReviews,vol.28,no.1,pp.20– 47,
  108. (2010). Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study,”
  109. (2007). TP53 mutations and hepatocellular carcinoma:ISRN Oncology 11 insights into the etiology and pathogenesis of liver cancer,”
  110. (2009). Treatment of hepatocellular carcinoma by radioembolization using y microspheres,” Digestive Diseases,
  111. (1999). u,andJ.Bruix,“Prognosisofhepatocellular carcinoma: the BCLC staging classification,”
  112. (2009). uen,J .L.H ou,andA.Chutaputti,“H epatocellularcar -cinomaintheAsiapacificregion,”JournalofGastroenterology and Hepatology,
  113. (1997). Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinomainchildren,”NewEnglandJournalofMedicine,vol.
  114. (2010). W2010orld gastroenterology organization guideline. Hepatocellular carcinoma(HCC):aglobalperspective,”JournalofGastrointestinal and Liver Diseases,
  115. (2006). Wnt/frizzled signaling in hepatocellular carcinoma,”
  116. Wnt/β-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology,”Future Oncology,vol.4,no.5,pp.647–660,2008.
  117. (2008). Wnt/β-catenin signaling pathway and its role in hepatocellular carcinoma,”
  118. (2008). Y.TakigawaandA.M.Brown,“Wntsignalinginlivercancer,” Current drug targets,
  119. (2002). Z h a o ,Z .M .M a ,X .R .Z h o u ,Y .Z .F e n g ,a n dB .S . Fang, “Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.